Allergan Inc.

allergan inc. - All News and Analysis

• Pharma Roundup: Roche and Novartis CEO Predictions, ImClone Cuts, and More

  BNET - 2008-12-08

  Roche CEO sees industry trouble, Novartis CEO wants to stay, ImClone cuts reps, Allergan eyelash-lengthener gets thumbs up. by John Maas

  Tags: Roche Holding AG, Forbes, Novartis AG, Allergan Inc., CEO, Federal Government, Strategy, Sales Strategy, Mergers & Acquisitions, Sales Force Management, Government, Management, Sales, Investment, Finance, John Maas

• The Pfizer-Allergan Deal Worst-Case Scenario

  BNET - 2008-12-05

  CNBC Mad Money host Jim Cramer suggested recently that Pfizer ought to acquire Allergan, maker of Botox and Juvederm. Cramer is usually not worth listening to but this idea has some merit: A tie-up of the two companies has advantages for both. However, mergers don't always go as planned, so...

  Tags: Pfizer Inc., Allergan Inc., Cramer, Sales Strategy, Mergers & Acquisitions, Gender And Diversity, Federal Government, Sales Force Management, Sales, Investment, Finance, Human Resources, Government, Jim Edwards

• Medicis Squeezed in Vanity Pharma Death Match vs. Allergan and J&J

  BNET - 2008-12-02

  Medicis may find itself on the losing side of the vanity pharma death match now that Johnson & Johnson has waded in with what will soon be a full suite of silicone breast implants, wrinkle fillers and botulinum toxin line smoothers. J&J on Monday agreed to acquire implant maker Mentor...

  Tags: Johnson & Johnson, Pharmaceutical Company, Allergan Inc., Mentor Corp., Sales Strategy, Sales Force Management, Sales, Jim Edwards

• Pharma Roundup: Novartis Courts India, Allergan Partners With Spectrum, and More

  BNET - 2008-10-30

  Novartis tempts India's brightest; Allergan and Spectrum forge $345 million partnership; insurance shares the guilt of doctor compensation; judge denies expedited Lilly/ImClone lawsuit. by John Maas

  Tags: India, Novartis AG, Allergan Inc., Spectrum, Business Structures, Insurance, Financial Planning, Benefits, Finance, Business Operations, Corporate Insurance, Human Resources, John Maas

• Allergan Inc. F3Q08 (Qtr End 9/30/08) Earnings Call Transcript

  Seeking Alpha - 2008-10-29

  Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question is from Ronny Gal of Bernstein Research. Ronny Gal Hi, good morning guys. First, David, are we okay in assuming that the bottom of that guidance range for '09 assume kind of early approval for Roloxin and...

  Tags: Efficacy, Call Transcript, Allergan Inc., Earnings, Taxes, Financial Planning, Finance, Seeking Alpha

• Earnings Preview: Allergan

  Seeking Alpha - 2008-10-28

  Allergan AGN is expected to report Q3 earnings before market open Wednesday Oct. 29 with a conference call scheduled for 8:00 am. Guidance Analysts are looking for a profit of 65c on revenue of $1.11B. The consensus is 63c to 66c for EPS, and revenue of $1.09B to $1.14B, according...

  Tags: Revenue, Allergan Inc., Earnings, Seeking Alpha, Operational Accounting, Finance, theflyonthewall.com, Healthcare

• Allergan's Eyelash Enhancer Makes Your Blue Eyes Brown

  BNET - 2008-10-27

  Allergan is hoping to turn its glaucoma drug, Lumigan, into a cosmetic treatment for longer eyelashes. Lumigan is currently approved only for preventing blindness. But it has one very odd side effect: patients' eyelashes become longer when using it. Unsurprisingly, doctors are already using it off-label...

  Tags: Eye, Allergan Inc., Lumigan, Jim Edwards

• Q&A With Medicis CEO Jonah Shacknai, Who Sees a "Definite Downturn" in Vanity Pharma

  BNET - 2008-10-06

  Medicis is going through a dramatic period. The vanity pharma company's Restylane dermal filler is in a battle royale with Allergan's Juvederm. It's waiting for FDA approval for Reloxin, its competitor to Allergan's Botox. And it just acquired LipoSonix, a high-intensity non-invasive ultrasound fat reducer. I talked...

  Tags: Accounting, Ernst & Young LLP, Restatement, Physician, Allergan Inc., Medicis, Sales Strategy, Operational Accounting, Financial Services, Sales, Finance, Jim Edwards

• Zacks Analyst Blog Highlights: AutoNation, Inc., Oscient Pharmaceuticals Corp., Equity Residential, ACADIA Pharmaceuticals Inc. and Allergan, Inc

  - 2008-10-03

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AutoNation, Inc. (NYSE: AN), Oscient Pharmaceuticals Corp. (Nasdaq: OSCI), Equity Residential...

  Tags: Acadia Pharmaceuticals Inc., Allergan Inc., analyst, AutoNation Inc., blog, Equity Residential, FINANCE, Investment, Nasdaq Stock Market Inc., New York Stock Exchange, Oscient Pharmaceuticals Corp., stock

• Medicis' Accounting Error Puts Spotlight on Solodyn Weakness; Allergan Rejoices

  BNET - 2008-09-25

  Medicis stock tumbled roughly 16 percent yesterday after it announced that it would restate six years of its numbers due to an accounting error. But the magnitude of the fall seems to have drawn attention not to the vanity pharma company's inability to count beans, but the...

  Tags: Accounting, Allergan Inc., Medicis, Solodyn, Operational Accounting, Financial Services, Sales Strategy, Finance, Sales, Jim Edwards

• Zacks Analyst Blog Highlights: Burger King Holdings, Inc., McDonald's Corp., Allergan, Inc., AutoZone, Inc. and Hudson City Bancorp

  - 2008-09-24

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Burger King Holdings, Inc. (NYSE: BKC), McDonald's Corp. (NYSE: MCD), Allergan,...

  Tags: Allergan Inc., analyst, AutoZone Inc., blog, Burger King Corp., FINANCE, Hudson, Investment, New York Stock Exchange, newsletter, stock

• Summer Surge for Pharma Powers IHE, but Concerns Remain

  Seeking Alpha - 2008-09-11

  Don Dion submits: Buoyed by some consolidation and seen as a safe haven in an uncertain market, healthcare stocks rallied hard in July and held their momentum into August. The sector cooled some during the last few weeks, but the S&P 500’s healthcare companies were still up...

  Tags: Healthcare, ETF, Abbott Laboratories Inc., Allergan Inc., Bristol-Myers Squibb Co., Barr Pharmaceuticals Inc., Johnson & Johnson, Eli Lilly & Co., Merck & Co. Inc., Pfizer Inc., Schering-Plough Corp., Wyeth

• The Allergan-Medicis Vanity Pharma Death Match Is About to Get Complicated

  BNET - 2008-09-08

  Imagine your drug company has the following problems: A portfolio of expensive, discretionary cosmetic products that Medicare and Medicaid won't reimburse for; it's under investigation by the Department of Justice for alleged off-label promotion; the recession is crimping consumers' desire to spend money on non-essential drug products;...

  Tags: Allergan Inc., Medicis, Gender And Diversity, Human Resources, Jim Edwards

• Allergan: When Deals Get Ugly

  Seeking Alpha - 2008-08-18

  Eben Tessari submits: What’s a billion between friends? The University of Georgia Research Foundation Inc. has filed suit claiming Allergan AGN screwed them out of a couple hundred million bucks for a drug that’s earned the company more than a billion dollars. by Eben Tessari

  Tags: Allergan Inc., Healthcare

• Allergan Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-07-30

  Question-and-Answer SessionOperator Operator Instructions. Our first question comes from Gary Nachman from Leerink Swann. Gary Nachman - Leerink Swann Hi, good morning. The first question is on RESTASIS. Was there was any stocking in the quarter for that product and could you update us on the IP front? Do...

  Tags: Allergan Inc.

• Zacks Analyst Blog Highlights: Lithia Motors, Ford, General Motors, Inspire Pharmaceuticals and Allergan Pharmaceuticals

  - 2008-06-10

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lithia Motors, Inc. (NYSE: LAD), Ford (NYSE: F), General Motors (NYSE:...

  Tags: Allergan Inc., blog, Ford Motor Co., General Motors Corp., New York Stock Exchange, pharmaceutical company

• Allergan Announces Agreement to Acquire Aczone® Gel 5%

  - 2008-06-09

  - - Acquisition Will Address Unmet Medical Need in Acne Therapies and Strengthen Allergan's Medical Dermatology Product Portfolio - -

  Tags: agreement, Allergan Inc.

• Allergan Announces Intent to File New Drug Application for Bimatoprost as Novel Treatment to Stimulate Natural Eyelash Growth

  - 2008-06-04

  IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) announced today that it intends to file a New Drug Application by end of the third quarter of 2008 with the U.S. Food and Drug Administration FDA for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth. Allergan has completed its...

  Tags: Allergan Inc.

• Economic Concerns Weighing Down Allergan

  - 2008-05-12

  HEALTHCARE: Implants boost cosmetic sales, small part of unit

  Tags: Allergan Inc.

• Allergan, Inc. Q1 2008 Earnings Call Transcript

  Seeking Alpha - 2008-05-08

  Question-and-Answer SessionOperator Thank you. Our first question comes from Frank Pinkerton of Bank of America. Sir, your line is open. Mr. Pinkerton. Frank Pinkerton - Banc of America Securities Thanks. Sorry. Can you hear me? David Pyott Yes. Just some quick questions on BOTOX please....

  Tags: Allergan Inc.

• Incorporated: 1948
• CEO: Mr. David E.I. Pyott